Artivion (NYSE:AORT) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Artivion (NYSE:AORT) in a report issued on Monday,Benzinga reports. Needham & Company LLC currently has a $58.00 price objective on the stock.

AORT has been the subject of a number of other reports. Oppenheimer reissued an “outperform” rating and set a $50.00 price objective on shares of Artivion in a report on Friday, November 7th. Citigroup reaffirmed an “outperform” rating on shares of Artivion in a research report on Friday, October 10th. Canaccord Genuity Group reiterated a “buy” rating and set a $51.00 price target on shares of Artivion in a report on Wednesday, December 17th. JMP Securities increased their price target on Artivion from $42.00 to $47.00 and gave the company a “market outperform” rating in a research report on Friday, October 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artivion in a report on Wednesday, January 21st. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.11.

Artivion Stock Performance

AORT opened at $41.16 on Monday. Artivion has a 1-year low of $21.97 and a 1-year high of $48.25. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -171.48 and a beta of 1.59. The company’s fifty day moving average price is $44.71 and its two-hundred day moving average price is $42.40. The company has a current ratio of 3.93, a quick ratio of 2.88 and a debt-to-equity ratio of 0.50.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. Artivion had a negative net margin of 2.16% and a positive return on equity of 5.98%. The firm had revenue of $113.39 million during the quarter, compared to analysts’ expectations of $110.71 million. Artivion’s quarterly revenue was up 18.9% compared to the same quarter last year. On average, analysts expect that Artivion will post 0.37 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Jean F. Holloway sold 10,000 shares of the stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $46.18, for a total transaction of $461,800.00. Following the completion of the transaction, the senior vice president owned 169,169 shares in the company, valued at approximately $7,812,224.42. This represents a 5.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO James P. Mackin sold 34,210 shares of the firm’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $45.86, for a total transaction of $1,568,870.60. Following the sale, the chief executive officer owned 800,993 shares of the company’s stock, valued at $36,733,538.98. This trade represents a 4.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 234,511 shares of company stock worth $10,612,452 over the last 90 days. Company insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On Artivion

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Artivion by 4.7% during the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock valued at $144,588,000 after purchasing an additional 141,030 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Artivion by 22.8% in the second quarter. Bank of America Corp DE now owns 645,070 shares of the company’s stock worth $20,062,000 after purchasing an additional 119,634 shares in the last quarter. Invesco Ltd. raised its position in shares of Artivion by 40.8% in the second quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after purchasing an additional 139,370 shares during the period. Two Sigma Investments LP lifted its stake in shares of Artivion by 235.5% during the 3rd quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock valued at $18,906,000 after buying an additional 313,446 shares in the last quarter. Finally, Kennedy Capital Management LLC lifted its stake in shares of Artivion by 19.0% during the 3rd quarter. Kennedy Capital Management LLC now owns 437,792 shares of the company’s stock valued at $18,536,000 after buying an additional 70,030 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.